抑郁与自杀行为报告与HIV整合酶抑制剂的关联:一项全球药物警戒研究
该研究基于WHO全球个例安全性报告数据库VigiBase,采用病例/非病例不比例分析,评估HIV整合酶抑制剂(INSTI)与其他抗逆转录病毒治疗相比抑郁与自杀倾向的报告风险。结果显示INSTI暴露者抑郁报告OR为3.6(95%CI 3.2-4.0),自杀倾向报告OR为4.7(95%CI 4.1-5.4),作者认为抑郁与自杀倾向是所有INSTI的不良反应,尤其多替拉韦,可能发生在治疗最初数月内。
要点
- INSTI暴露者抑郁报告OR 3.6(95%CI 3.2-4.0),高于其他ART。
- INSTI暴露者自杀倾向报告OR 4.7(95%CI 4.1-5.4),高于其他ART。
- 比克替拉韦和多替拉韦抑郁报告显著更高,自杀倾向仅多替拉韦显著更高。
核心结论
- 作者认为抑郁与自杀倾向是所有INSTI的不良反应,尤其多替拉韦,可能发生在治疗最初数月内。
研究设计与样本
- 基于WHO全球个例安全性报告数据库VigiBase的全球药物警戒研究,采用病例/非病例不比例分析评估INSTI与其他ART相比抑郁与自杀倾向的报告风险。
- 研究期间共19 991 410份报告,其中124 184份涉及暴露于ART的患者,包括22 661例暴露于INSTI的患者。
主要发现
- 在INSTI治疗患者中,识别出547例抑郁和357例自杀倾向病例。
- 不比例分析显示,与使用其他ART相比,INSTI使用者抑郁报告OR为3.6(95%CI 3.2-4.0),自杀倾向报告OR为4.7(95%CI 4.1-5.4)。
- 在INSTI中,比克替拉韦和多替拉韦的抑郁报告显著更高,而自杀倾向报告仅多替拉韦显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Concerns have been raised regarding neuropsychiatric adverse drug reactions of integrase inhibitors (INSTIs) in patients living with HIV. The aim of this study was to assess the risk of depression and suicidality reporting with INSTIs based on a global pharmacovigilance database. METHODS: Depression and suicidality cases in patients treated with INSTIs were identified within the WHO global database of individual case safety reports, VigiBase. Risk of depression and suicidality reporting with INSTIs compared with other ART was assessed using disproportionality analyses (case/non-case statistical approach). RESULTS: Of 19 991 410 reports over the study period, 124 184 reports concerned patients exposed to ART, including 22 661 patients exposed to an INSTI. Among patients treated with an INSTI, 547 cases of depression and 357 cases of suicidality were identified. Disproportionality analyses showed that depression [reporting OR (ROR) 3.6; 95% CI: 3.2-4.0] and suicidality (ROR 4.7; 95% CI: 4.1-5.4) were more reported with the use of INSTIs compared with other ART. Amongst INSTIs, depression reporting was significantly greater for bictegravir and dolutegravir, whereas suicidality reporting was significantly greater for dolutegravir only. CONCLUSIONS: Our findings suggest that depression and suicidality are adverse drug reactions of all INSTI agents, especially dolutegravir, which may occur within the first months of therapy.
引用
- Préta LH, Chroboczek T, Treluyer JM, et al. Association of depression and suicidal behaviour reporting with HIV integrase inhibitors: a global pharmacovigilance study. J Antimicrob Chemother. 2023. PMID: 37311223. doi:10.1093/jac/dkad187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。